Zosano Pharma Files Voluntary Petition for Relief Under Chapter 11
02 juin 2022 08h00 HE
|
Zosano Pharma Corporation
FREMONT, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that on June 1, 2022 it filed a voluntary...
Zosano Pharma Reports First Quarter 2022 Financial Results
13 mai 2022 16h00 HE
|
Zosano Pharma Corporation
FREMONT, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended...
Zosano Pharma Provides Corporate Update
29 avr. 2022 16h00 HE
|
Zosano Pharma Corporation
FREMONT, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today provided a corporate update. On April 14, 2022, the...
Zosano Pharma Announces Reverse Stock Split Effective Today
11 avr. 2022 08h00 HE
|
Zosano Pharma Corporation
FREMONT, Calif., April 11, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its Board of Directors has approved a...
Zosano Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results
17 mars 2022 16h05 HE
|
Zosano Pharma Corporation
FREMONT, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and...
Zosano Pharma Announces Pricing of $15.4 Million Public Offering of Common Stock and Warrants
08 févr. 2022 21h55 HE
|
Zosano Pharma Corporation
FREMONT, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced the pricing of its previously announced...
Zosano Pharma Announces Proposed Public Offering of Common Stock and Warrants
08 févr. 2022 16h10 HE
|
Zosano Pharma Corporation
FREMONT, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced that it is commencing an underwritten public...
CORRECTION - Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of a Trivalent Influenza Vaccine Formulated on its Transdermal Microneedle System Versus an Intramuscular Injection of the Vaccine at a Higher Dose
05 janv. 2022 12h01 HE
|
Zosano Pharma Corporation
FREMONT, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- In a press release published under the same headline today by Zosano Pharma Corporation (Nasdaq:ZSAN), a measurement was incorrectly stated as...
Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of a Trivalent Influenza Vaccine Formulated on its Transdermal Microneedle System Versus an Intramuscular Injection of the Vaccine at a Higher Dose
05 janv. 2022 09h20 HE
|
Zosano Pharma Corporation
FREMONT, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the publication of Phase 1 clinical trial...
Zosano Pharma Announces Changes to Board of Directors; Appoints Cross Functional Business Executive Elaine M. Yang
13 déc. 2021 16h30 HE
|
Zosano Pharma Corporation
FREMONT, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced changes to its board of directors, including...